Company Analysis
Sign in

NewcelX Ltd. (NCEL)

Nasdaq: NCEL · Pharmaceutical Preparations · Zurich · filing with the SEC since 2019
Full chart Alerts Compare
Grade4.5
◀ Past 4.3● Present 4.5▶ Future 4.6
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-$8.3M-15.3%
Earnings per share$2.16-11.1%
Operating cash flow-$2.8M-159.5%
Cash$2.2M+238.6%
Debtn/a
Shareholders’ equity$7.3M+190.7%
Shares, diluted3,843,984+30.1%
Return on equity-114.5%
The recordfrom its filings
Filings in 202648
Newest filingNov 9 · 6-K
Annual reportApr 29, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$400,000
Patents granted5
Filer categoryNon-accelerated filer<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
1819202122232425
As filed, in USD. Nothing here is a forecast.

News

Sep 22, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
Aug 26, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton NCEL · research, not advice